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Background: Better treatments are urgently needed for the management of Ebola virus epidemics in Equatorial
Africa.
Methods: We conducted a systematic review of the literature on the use of passive immunotherapy for the treatment
or prevention of Ebola virus disease. We placed findings from this review into the context of passive immunotherapy
currently used for venom-induced disease, and recent improvements in manufacturing of polyvalent antivenom products.
Results: Passive immunotherapy appears to be one of the most promising specific treatments for Ebola. However, its
potential has been incompletely evaluated, considering the overall experience and recent improvement of
immunotherapy. Development and use of heterologous serum derivatives could protect people exposed to Ebola viruses
with reasonable cost and logistics.
Conclusion: Hyperimmune equine IgG fragments and purified polyclonal whole IgG deserve further consideration as
treatment for exposure to the Ebola virus.
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The epidemic of Ebola virus disease (EVD) currently tak-
ing place in West Africa has revived debate on the treat-
ment of this severe infection [1]. Experimental treatment
consisting of monoclonal antibodies has been used com-
passionately in half a dozen infected medical workers
[2]. However, the efficacy and safety of these antibodies
have not yet been evaluated in humans, and available
quantities allow treatment of only a few patients. The
small amount available and the anticipated high cost
have precluded benefit for many patients, raising an add-
itional serious problem of equity. During a WHO meet-
ing in September 2014, experts agreed that developing
treatments based on blood products from convalescent* Correspondence: jean-philippe.chippaux@ird.fr
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unless otherwise stated.human patients was a priority [1]. However, heterologous
animal products are not under clinical investigation.
Passive immunotherapy of animal origin has been used
for over 120 years to treat bacterial and viral infections,
envenomations and drug intoxications [3]. Its use de-
creased following the development of vaccination and
antibiotics, with the notable exception of rabies, for
which treatment with immune globulin remains frequent
in Africa, Asia and Latin America [4,5]. Improvements in
manufacturing through fragmentation and purification of
immunoglobulin G (IgG), viral inactivation, lyophilization,
and better understanding of pharmacokinetics have led to
safer and more efficient products. Consequently, experi-
ence with millions of antivenom treatments annually of-
fers a successful model now applicable to the treatment of
EVD [6,7].
Passive immunotherapy of EVD has had insufficient
consideration given to its conditions of use, benefits and
limitations, including pharmacokinetics, potency, and
dose. In the particular context of Ebola and the political,
social and economic constraints of endemic countries,ral. This is an Open Access article distributed under the terms of the Creative
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proach to disease management. Production of monoclo-
nal antibodies is expensive and sometimes of low yield,
significantly reducing the number of potential beneficiar-
ies. Experience during EVD epidemics in Africa has in-
volved insufficient resources and limited management
capabilities by national health services. Under such cir-
cumstances, there are significant potential benefits in
using equine polyclonal IgG fragments. Their manufac-
ture is well standardized and inexpensive, compared to
recombinant monoclonal antibodies. Moreover, their use
can be managed directly by health personnel in at risk
countries, enabling a more tailored and flexible response.
This study presents the arguments in favor of passive
immunotherapy to control EVD after exposure, i.e. dur-
ing either the incubation of the disease, or the disease it-
self. Polyclonal equine antibodies offer multiple potential
benefits, including remarkable tolerance, availability, and
ease of use. More importantly, such a treatment can be
produced at a price affordable to the impoverished com-
munities facing epidemic EVD.
Review
African Ebola virus and EVD
Ebola viruses belong to the family Filoviridae, which also
includes Marburgvirus and Cuevavirus [8,9]. The incu-
bation period ranges from 3 to 21 days and the illness
lasts from 5 to 15 days. The disease starts abruptly with
nonspecific symptoms that can be mistaken for other
common diseases in Equatorial Africa such as malaria,
yellow fever, typhoid or influenza [10]. Case fatality rates
are very high although variable (between 20 and 80%)
according to viral strain and possibly other factors such
as the number of viral generations, mode of transmis-
sion, and availability of effective supportive care.
History of passive immunotherapy of EVD
Behring and Kitasato [11] described passive immunother-
apy, originally called “serum therapy” because it involved
administration of whole serum, in 1890. Subsequently
many diseases, including viral ones, benefited from serum
therapy [3]. This gradually became “immunotherapy” as
process improvements were introduced: precipitation of
immunoglobulins, enzymatic digestion, and steps to re-
duce microbial contamination and purify the final product
[6]. After the widespread introduction of antibiotics and
immunization, however, heterologous immunotherapy was
largely abandoned as an infectious disease treatment strat-
egy [12]. Subsequently, the technology was advanced pri-
marily for the purpose of neutralizing snake and scorpion
venom.
Several therapeutic protocols for EVD have recently
been suggested [13]. The first attempt to treat EVD with
convalescent plasma was undertaken during the 1976epidemics in Sudan and Democratic Republic of Congo
(DRC). During these epidemics, a plasmapheresis pro-
gram for obtaining convalescent plasma was imple-
mented [14]. A Congolese patient with confirmed EVD
received 500 mL of convalescent plasma (about 6 g IgG)
and survived [10]. In addition, laboratory contamination
occurred in Great Britain with samples from outbreaks.
Six days after exposure (D6), clinical signs appeared in
exposed people, corresponding to peak viremia. Inter-
feron and symptomatic care were provided, without ap-
parent improvement. On D8, 450 mL of convalescent
plasma was administered to victims, with a second dose
(330 mL) on D11 (i.e. nearly 10 g IgG). Clinical improve-
ment occurred on D13, along with a significant decrease
in viral load that disappeared on D15. Symptoms re-
solved on D18 and convalescence lasted 10 weeks [15].
It was not possible to draw firm conclusions from these
two cases, especially since the second patient recovered
within a period compatible with a natural recovery.
During the 1995 outbreak in Kikwit (DRC), eight patients
received transfusions of convalescent human plasma, ran-
ging from 150 to 450 mL (1.5 to 5 g IgG), 4–15 days after
the onset of clinical signs, and seven survived [16]. Again,
results were not considered conclusive, because of small
sample size and variable timing.
Dye et al. [17] treated three monkeys during the clin-
ical phase of the disease using polyclonal IgG from mon-
keys that had survived an infection with Ebola virus in
controlled conditions. The monkeys showed minimal ill-
ness, followed by full recovery.
Goats and horses were hyperimmunized with the cul-
ture medium and extracts of monkey liver infected with
Zaire ebolavirus [18]. Purified IgG protected experimen-
tally infected guinea pigs and baboons. In addition, goat
hyperimmune IgG was given to four persons who were
accidentally exposed to infectious laboratory materials,
without any confirmation of contamination. Horse IgG
was also evaluated independently in a Macaca cynomolgus
model. In these monkeys, viremia and clinical signs ap-
peared later than in controls showing a reduced replica-
tion of the virus but not complete stop, despite use of
interferon with passive immunotherapy [19].
During the Kikwit outbreak, human monoclonal anti-
bodies were constructed according to the techniques of
“phage display” from two patients’ bone marrow RNA
[20]. These antibodies react with the nucleoprotein, en-
velope glycoprotein and non-structural secretory glyco-
protein secreted by infected cells. It was observed that
neutralizing antibodies are produced at a relatively low
yield during infection, which could partly explain the
failure of some treatments using convalescents’ plasma [21].
A mixture of two chimeric monoclonal antibodies
(ch133 and ch226) against Zaire ebolavirus was effective
in rodents, but protected only one out of three infected
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venously administered (50 mg per animal), 24 and
72 hours after viral challenge. Monoclonal antibodies
remained detectable in the blood of surviving animals
until the appearance of antibodies induced by the infec-
tion. In contrast, the serum concentration of monoclonal
antibodies became undetectable at the terminal stage of
the disease in the two monkeys that died due to the infec-
tion whereas viremia increased inversely. This suggests
that the virus consumes large amounts of neutralizing
antibodies.
A combination of three neutralizing monoclonal anti-
bodies (1H3, 2G4, and 4G7) directed against two glyco-
proteins and one secretory glycoprotein of Ebola virus
was used in a Macacus cynomolgus model [23]. Four in-
fected monkeys survived following treatment with the
monoclonal antibody administered (25 mg · kg−1) three
consecutive days starting 24 hours after the viral chal-
lenge. The same treatment, starting 48 hours after infec-
tion, resulted in two deaths out of four macaques,
suggesting late treatment is less effective because either
the pathogenic effects are more developed or the dose
was insufficient compared to the amount of virions.
Three chimeric humanized monoclonal antibodies against
Ebola virus (c13C6, h-13 F6, and c6D8; their combination is
known as MB-003) were produced by an ovarian cell line of
the Chinese hamster (Cricetulus griseus) and a whole plant,
Nicotiana benthamiana [2]. The antibodies of these two sys-
tems, respectively at doses of 50 mg · kg−1 and 16.7 mg · kg−1,
protected rhesus monkeys from lethal viral challenge when
administered one hour prior to treatment. Protection was
significant when monoclonal antibodies were administered
24 and 48 hours after infection. In all experiments, surviving
animals showed no viremia and few or no clinical symptoms
[2]. This monoclonal antibody cocktail, composed of one
component from the MB-003 mixture and two from ZMab
(consisting of murine mAbs m1H3, m2G4 and m4G7), has
been used recently in some patients from the West African
epidemic, under the name ZMapp™. In another study with
nonhuman primates, three doses of 50 mg · kg−1 of an opti-
mized combination of ZMapp™ have been administered every
three days, resulting in the recovery of six monkeys infected
with 2,512 PFU three days before the first injection of
ZMapp™, during which time they developed viremia and
signs of infection [24].
Strategy for passive immunotherapy and prophylaxis of
EVD
Post-exposure treatment of EVD may well be compared to
the post-exposure treatment of other viral diseases such as
rabies. However, there are two main differences. First, the
Ebola virus spreads in the body much faster than the ra-
bies virus. In the post-exposure situation, this increases
the relative importance of rapid administration of passiveimmunotherapy as opposed to active immunization with a
vaccine that will not have time to act [25]. Second, unlike
the rabies virus, Ebola virus is not sequestered in the ner-
vous system where antibodies cannot penetrate, which has
advantageous implications both for the site of injection
and for the bioavailability of neutralizing antibodies [25].
Convalescent human plasma, recently reconsidered, is
difficult and dangerous to collect and administer [1].
Filovirus persist several weeks in the body after recovery
[26]. In addition, antibody titers appear to be too low for
good protection. Obtaining antibodies from another
source remains crucial.
Production and use of animal-derived immunothera-
peutic agents is a complex process dependent on many
factors. The quality and specificity of immunogens, host
species, and individual immune response determine the
neutralization titer, and consequently the potency and
efficacy of the preparation [6,7]. Enzymatic digestion of
IgG, purification and elimination of potentially infectious
agents improve the safety of the product [27]. The thera-
peutic dose depends not on the patient’s body weight,
but on the amount of antigen present in the body and
its tissue distribution. The distribution of antibodies is
related to their composition (whole IgG or IgG frag-
ments) and their route of administration [28,29]. IgG
and F(ab’)2 remain in the compartment where they are
introduced, whereas smaller fragments including Fab or
Fv have a greater volume of distribution. Sufficient blood
concentration of antibodies enables the gradual transfer
of antigens from the peripheral compartments towards
the blood where they are bound and cleared [28,30]. In
addition, the half-life of IgG and F(ab’)2 is 5 to 10 times
longer than that of the Fab or Fv, which require more
frequent dosing [28].
Implementation of passive immunotherapy can be di-
vided into seven steps:
1. Antigen production
The use of culture medium or extracts from Ebola-
infected animal organs does not seem a promising strat-
egy since the process involves substantial risks [18].
Therefore, it is preferable to produce isolated virus pro-
teins–possibly recombinant– or proteins vectorized by a
non-pathogenic virus.
The selection of immunogens is logically directed to
proteins involved in the infectious capacity of Ebola
virus, such as the glycoproteins, or those that have high
pathogenicity, such as VP24 and VP35 viral proteins.
The main limitations of this approach involve the speci-
ficity of these proteins and the ability of the antibodies
produced against them to neutralize viruses belonging to
other species. It may be preferable to have polyvalent
antibodies, as in the case of antivenoms [6,7]. Among
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ology of amino acid composition is 55 to 70% for the
glycoproteins and VP24 or VP35 viral proteins, which
requires measuring the level of paraspecificity among
the different species of Ebola virus or identifying con-
served structures involved in immunogenicity [31].
Immunogens may be recombinant proteins or expressed
by a recombinant vesicular stomatitis virus (rVSV), or
other recombinant virus, carrying Ebola virus antigens.
Immunization with recombinant rVSV generated cross-
immunity in different species of Ebola virus, although such
immunization should ideally involve a cocktail of antigens
[32-34]. The rVSV models appear to be effective and
harmless to the host [35].
In addition, immunogens should be capable of indu-
cing a good immune response both quantitatively and
qualitatively. Five epitopes involving monoclonal anti-
bodies protective against Ebola virus in the murine
model have been identified in the glycoprotein of Ebola
virus, one of which is conserved in all known Ebola vi-
ruses [36]. These genetically engineered proteins have
shown high immunogenicity [37]. However, Ito et al.
[38] showed that the glycoprotein can inhibit the secretory
specific neutralizing antibodies against the envelope glyco-
protein. It appeared that the epitopes of both proteins cor-
responding to neutralizing antibodies were similar and
that the secretory glycoprotein served as decoy for neu-
tralizing antibodies. The study of the mechanisms of
neutralization by monoclonal antibodies showed that they
inhibited viral transduction by two different routes [39].
Neutralization by one of them (KZ52) inhibits the endoso-
mal proteolytic activity necessary for Ebola virus penetra-
tion into the cell. Another monoclonal antibody (JP3K11)
inhibits the melting and/or binding of the membrane recep-
tor by the structural glycoprotein. According to the authors,
antibodies that recognize the reduced post-glycoprotein, as
JP3K11, could be more effective.
Furthermore, Bale et al. [40] showed that access of the
antibody against the corresponding epitope and the af-
finity for the antigen were important to explain the neu-
tralizing capacity of the antibody.
2. Animal immunization
The horse is the animal most used in production of
hyperimmune sera because of the ease of management,
high antibody yield and low risk of human contamination
by virus or unconventional infective agents. Immunization
itself is standardized and performed under optimal condi-
tions for both personnel and animals [6,7]. With optimal
animal husbandry, titers of neutralizing antibodies pro-
duced in hyperimmunized horses may exceed those ex-
pected from simple immunization, by a factor of 10- to
20-fold (A. Alagón, unpublished data).3. Immunological tests
Although increased antibody titers in immunized ani-
mals are assessed by ELISA, neutralizing capacity must
be determined in an appropriate animal model (rodents
or primates) or cell culture using rVSV carrying Ebola
virus proteins [41].
It is likely that the neutralization titer and/or the dose
of antibodies used in experiments conducted to date
have been insufficient. In some of them, inappropriate
doses or administration routes may have not resulted in
a sufficient plasma concentration of antibodies to neutralize
the virus during the course of the disease. Similarly, long in-
tervals between serial doses of monoclonal antibodies could
result in ineffective sustained levels to prevent virus replica-
tion, limiting the effect of passive immunotherapy. Both
phenomena have been observed in treatment of snakebite
envenomation, in which repeated doses of antivenom are
sometimes required to overcome pharmacokinetic-
toxicokinetic mismatch. There is, however, a dramatic
difference in the expected amount of antibodies be-
tween viral infection and envenomation. In the latter,
the amount of venom injected and final antigen con-
centrations in the body decrease with natural clear-
ance of the venom and, optionally, neutralization by
antivenom [6]. In contrast, during a viral infection, the
virus replicates and the amount of antigen increases
exponentially. Consequently, the concentration of anti-
bodies in the body must be very high to neutralize viral
antigens, particularly if treatment is initiated late in the
course of disease. Dose and frequency of antibody admin-
istration must take such factors into consideration, mean-
ing that treatment of fulminant Ebola could involve larger
quantities of antibodies than previously administered.
4. Fragmentation and purification of IgG
Some manufacturers are specialized in production of
heterologous antibody fragments at a reasonable cost.
Production is now standardized and risks resulting from
the use of well-purified IgG fragments are trivial com-
pared to the historical experience with whole IgG [7].
Currently, it is possible to administer more than 500 mg
of antibody or even several grams, with a low incidence
of adverse events, most of them mild [27]. The incidence
of side effects from equine antivenom administration
has been reduced from 80% (with nearly 25% of anaphyl-
actic shock) with whole IgG preparations, to less than
10% of mild reactions with highly purified IgG fragments
[27]. Highly purified equine IgG fragment preparations
are now used safely for treatment of snakebite in
Africa [7].
5. Formulation and dosage of passive immunotherapy
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should consider the distribution in the different com-
partments of the body, and their respective half-life as
well as mechanisms of action. F(ab’)2 remains longer
than Fab in the blood compartment, where it binds with
antigens rapidly cleared by the reticuloendothelial sys-
tem [28,30]. Furthermore, F(ab’)2 remains five to six
times longer in the body than Fab, thereby reducing the
frequency of required dosing. Moreover, although Fab
may form a complex with antigen in any body compart-
ment, it must return to the plasma compartment for
clearance; this may be problematic, depending on the
size of the immune complex. Whole IgG offers the po-
tential advantage of complement-dependent cytotoxicity
(CDC) and antibody-dependent cellular cytotoxicity
(ADCC) in addition to the steric hindrance afforded by
Fab and F(ab’)2 fragments, with a necessary trade-off in
characteristics that may warrant comparative in vivo
studies. Fab and F(ab’)2 fragments cannot mediate
antibody-dependent enhancement of infection with
Ebola virus, which involves interaction between whole
IgG and the Fc receptor or complement C1q and the
C1q receptor [42].
The pharmacokinetics of whole IgG or its fragments
are not determined by the epitopes of antigen recogni-
tion. Intravenous administration of IgG fragments, what-
ever their composition, guarantees rapid delivery, with a
bioavailability close to 100%, either in the blood com-
partment for F(ab’)2, or in all the compartments for Fab
[28,30]. Intramuscular administration of F(ab’)2 results
in a slow and partial (about 50%) spreading of the inocu-
lum from the injection site. This is useful if a gradual re-
lease of antibodies is desired (e.g. in anticancer drugs),
rather than immediate, as for the treatment of envenom-
ation or active infections [29].
Dose should be based on total antigen load, in this
case viremia, rather than body weight or volume. During
envenomation, antigen load may be estimated statisti-
cally (relative to the average venom yield of the snake)
or based on the rapidity of onset and severity of clinical
symptoms. Typically, one vial of antivenom contains
200 mg of antivenom F(ab’)2 to be diluted in 10 mL of
solvent, which corresponds to approximately 300 mg of
IgG. However, it is possible to increase the protein dose
of each vial and to adjust the dilution and rate of admin-
istration to limit the occurrence of undesirable effects.
6. Clinical trials
For forty years, therapeutic use of purified IgG frag-
ments has been well established [7]. Manufacturing
practice must be sufficiently well controlled to allow use
in humans. However, the specificity of antibodies with
respect to antigenic epitopes does not affect their safetyand tolerability and, therefore, these are not limiting fac-
tors in new product development. Accordingly, as in the
case of antivenoms, phase I studies are not required.
Phase II trials of candidate products in patients or per-
sons who have been in contact with EVD cases could be
ethically permitted, under proper conditions and new
WHO recommendations [1]. In compassionate treatment
of a highly lethal disease, and subject to the opinion of an
ethics committee and administrative authorization by ap-
propriate health authorities, it would be possible to treat
many patients relatively quickly after preclinical testing.
As in the case of antivenom, concurrent controls would
not be necessary, unless there is another treatment for
comparison [43]. In the event of promising animal data, in
which use of a placebo would be unethical, clinical im-
provement and reduction of viremia could be measured
against historical expectations. Finally, pragmatic clinical
trials – not explanatory – may be more appropriate [44].
7. Distribution and storage of F(ab’)2
Lyophilized F(ab’)2 products have an estimated room
temperature shelf life of 3 to 5 years depending on the
pharmacopoeia policy, but they actually retain potency
much longer [6]. These could be stored in each endemic
country, ready to use on short notice in the event of an
epidemic. Current production capacity exceeds several
hundred thousand doses annually, which means that a
practical scale-up at existing facilities could provide an
adequate supply.
Approximate cost can be anticipated, based on the
current production and sale of antivenoms in Africa.
Following initial development, 600 milligrams of specific
F(ab’)2 (corresponding to approximately 1 g of specific
IgG) would cost about US$ 65–80, in contrast with the
usual cost of monoclonal antibodies [45].
Conclusion
Hard to control due to the current health and socioeco-
nomic contexts, EVD outbreaks represent an emerging
and growing public health problem in sub-Saharan Africa.
The delay in development of an effective and accessible
therapy shows the inability of the international community
to mobilize effectively, despite an unprecedented scale.
Passive immunotherapy, although tested in early out-
breaks in Sudan and DRC, has still not been fully evalu-
ated. Long experience with the use of antivenom could be
used to reformulate the conditions and procedures for the
use of highly purified equine specific IgG fragments to
treat persons exposed to the Ebola virus or affected by
EVD. A treatment protocol inspired by the existing stand-
ard for post-exposure management of rabies could be ap-
plied, taking into account the distinct characteristics of
EVD, such as the speed of viral replication and the
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IgG fragments.
If an F(ab’)2 proves to be effective, the implementation
of a strategy for controlling epidemics by passive immuno-
therapy will be accessible, relatively inexpensive, and easily
applicable.
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